Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells
Giuseppa Augello(Institute for Biomedical Research and Innovation), Melchiorre Cervello(Foundation for Biomedical Research)
Cited by 47
Related Papers
NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance
|Cell Death and Disease|2016|141
Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation
|International Journal of Oncology|2017|94
Nanostructured Lipid Carriers-Containing Anticancer Compounds: Preparation, Characterization, and Cytotoxicity Studies
|Drug Delivery|2007|72
Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells
|PLoS ONE|2013|50
New Insights into the Behavior of NHC-Gold Complexes in Cancer Cells
|Pharmaceutics|2023|27